The revenue miss and guidance cut signal a material deceleration in the core RNS business. Watch for Q4 scheduled case recovery and the IGE PMA-S amendment submission around year end as key catalysts. The positive Adjusted EBITDA milestone provides some cost structure confidence but does not offset the top-line disappointment.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $7.56entry
- T+1 · yesterday +5.42%α +7.33% · $7.97
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NeuroPace reported Q3 2026 total revenue of $23.1M, down 1.1% YoY, and RNS System revenue growth of only 1.4%, well below prior expectations. The company slashed full-year 2026 revenue guidance to $91M-$92M from $99.5M-$101.5M, citing isolated account-level issues and field organization disruption. GAAP net loss improved to ($3.3M) from ($4.9M) a year ago, and the company achieved positive non-GAAP income from operations of $0.4M for the first time.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $23.1M, down 1.1% YoY from $23.4M
- RNS System revenue $22.9M, growth of only 1.4% YoY
- Full-year 2026 revenue guidance revised to $91M-$92M from $99.5M-$101.5M
- Adjusted EBITDA turned positive at $0.4M vs ($1.3M) in Q3 2025
- Non-GAAP gross margin improved to 84.8% from 82.8%
- Cash and investments $49.5M at quarter end, down from $51.9M prior quarter
- IGE PMA-S amendment submission expected around year end after FDA SIR meeting
- Remote Care PMA-S submitted to FDA with 180-day review cycle
Financial Impact
Revenue guidance cut by ~$9M (9%) at the midpoint; Q3 revenue missed consensus by ~$4.1M (15%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| RNS System | $22.9M | +1.4% |
| Service | $203.0K | Not reported |
Risk Factors
- Revenue growth deceleration to 1.4% from historical 20%+ rates
- Full-year guidance cut of ~$9M at midpoint
- Field organization disruption may persist into Q4
- IGE indication expansion timeline uncertain after SIR meeting
- Cash burn continues with $49.5M in liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001528287-26-000037 |
| Document: npce-20261112.htm | 0001528287-26-000037 |
| Document: 0001528287-26-000037-index-headers.html | 0001528287-26-000037 |
| Document: 0001528287-26-000037-index.html | 0001528287-26-000037 |
| Document: 0001528287-26-000037.txt | 0001528287-26-000037 |
| 8-K Data (Synthetic) | 0001528287-26-000037 |
Track record
6 reports on NPCE
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today Insider Cluster Bullish 4/10 Entry $8.27 Now $8.20 −0.85% settles Nov 19
- Nov 17, 2026today Insider Buy Neutral 3/10 Entry $8.36 Now $8.20 −1.91% settles Nov 19
- Nov 12, 20265d ago 8-K Bearish 6/10 Viewing Entry $7.56 to $7.97 Now $8.20 −8.47% ▼ −5.42% −7.33% vs SPY
- Nov 9, 20267d ago Institutional Cluster Neutral 2/10 Entry $12.69 to $12.52 Now $8.20 −35.38% ▼ −1.34% −2.66% vs SPY
- May 12, 202627w ago 8-K Bullish 7/10 Entry $15.81 to $15.81 Now $8.20 −48.13% · 0.00% +0.00% vs SPY
- Apr 21, 202630w ago DEFA14A Neutral 3/10 Entry $16.98 to $16.87 Now $8.20 −51.71% ▼ −0.65% −0.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers